Mass Spectrometry-Based “Omics” Approaches in Cancer Research

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 25 November 2024 | Viewed by 209

Special Issue Editors


E-Mail Website
Guest Editor
Proteopath GmbH, Max-Planck-Str. 17, 54296 Trier, Germany
Interests: cancer; diagnostics; mass spectrometry; molecular pathology; “omics”
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Institute of Pathology, School of Medicine, Technical University of Munich, Trogerstr. 18, 81675 Munich, Germany
Interests: immunohistochemistry; hemato-oncology; uro-oncology; mass spectrometry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Over the past two decades, the words "omics" has expanded from the initial "genomics" to a wide range of biomolecular disciplines directed toward the study of RNA species (transcriptomics), proteins (proteomics), lipids (lipidomics), glycans (glycomics), and metabolites (metabolomics). The spread of omics disciplines has been possible mainly through the development of novel and high-throughput mass spectrometry technologies and informatics tools capable of generating large amounts of data related to different levels of biological complexity (DNA, mRNA, proteins, metabolites, etc.).

Emerging omics technologies are likely to influence the development of omics-based analysis of cancer in the future, as both the types and numbers of molecular measurements continue to increase. Furthermore, the combination of different omics approaches generates more comprehensive information, ultimately leading to a deeper understanding of cancer. There is a strong interest to push “omics” technologies in the direction of highly personalized medicine to achieve targeted therapies capable of halting tumor progression.

The purpose of this Special Issue is to deliver recent advances of mass spectrometry‐based “omics” application in cancer helping in biomarker discovery for early diagnosis, prognosis, and appropriate therapeutics.

Dr. Rita Casadonte
Dr. Kristina Schwamborn
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarker discovery
  • cancer
  • mass spectrometry
  • “omics”

Published Papers

This special issue is now open for submission.
Back to TopTop